产品说明书

Notoginsenoside R1

Print
Chemical Structure| 80418-24-2 同义名 : 三七皂苷R1 ;Sanchinoside R1;Sanqi glucoside R1;NG-R1
CAS号 : 80418-24-2
货号 : A171380
分子式 : C47H80O18
纯度 : 98%
分子量 : 933.127
MDL号 : MFCD00210535
存储条件:

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(112.52 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Notoginsenoside R1 (NR1), the main bioactive component in panaxnotoginseng, is reported to have some neuronal protective, antihypertensive effects. NR1 significantly reduce blood pressure in SHR (spontaneously hypertensive rats) and induce nitric oxide (NO) generation through increasing the phosphorylation of iNOS (inducible nitric oxide synthase) [3]. R1 is a novel cardioprotective agent that can attenuate adverse cardiac dysfunction, hypertrophy, and associated disorders, such as fibrosis. R1-supressed cardiac dysfunction, atherosclerotic lesions, and inflammatory cytokine accumulation in the myocardium can be partially inhibited by CCR2 (CC chemokine receptor 2) translation in bone marrow cells[4]. In addition, retinal vascular degeneration, reduced retinal thickness, and impaired retinal function in db/db mice were all dramatically attenuated by oral treatment with NGR1 (30 mg/kg) for 12 weeks. NGR1 pretreatment also significantly inhibited apoptosis, markedly suppressed the VEGF expression, markedly increased PEDF expression and markedly inhibited oxidative stress and inflammation in rat retinal Müller cells (rMC-1) subjected to high glucose (HG) and in the retinas of db/db mice[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02975076 Stroke, Acute ... 展开 >> Ischemic Attack, Transient 收起 << Not Applicable Not yet recruiting November 2019 -
NCT02316730 Healthy Phase 1 Completed - China, Sichuan ... 展开 >> West China Second University Hospital Chengdu, Sichuan, China, 610000 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.07mL

0.21mL

0.11mL

5.36mL

1.07mL

0.54mL

10.72mL

2.14mL

1.07mL

参考文献

[1]Gu B, Nakamichi N, et al. Possible protection by notoginsenoside R1 against glutamate neurotoxicity mediated by N-methyl-D-aspartate receptors composed of an NR1/NR2B subunit assembly. J Neurosci Res. 2009 Jul;87(9):2145-56.

[2]Zhang WJ, Wojta J, Binder BR. Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. Arterioscler Thromb Vasc Biol. 1997 Mar;17(3):465-74.

[3]Yang Y, Xi P, Xie Y, Zhao C, Xu J, Jiang J. Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457. Int J Clin Exp Pathol. 2015;8(3):2700-2709.

[4]Xiao J, Zhu T, Yin YZ, Sun B. Notoginsenoside R1, a unique constituent of Panax notoginseng, blinds proinflammatory monocytes to protect against cardiac hypertrophy in ApoE-/- mice. Eur J Pharmacol. 2018;833:441-450

[5]Zhou P, Xie W, Meng X, et al. Notoginsenoside R1 Ameliorates Diabetic Retinopathy through PINK1-Dependent Activation of Mitophagy. Cells. 2019;8(3):213.